Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Japanese Patients With Adult Onset Still's Disease
NCT04717635Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2021
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in adult-onset Still's disease (AOSD), sponsored by Novartis. Primary endpoint: Adapted American College of Rheumatology 30 Response at 8 weeks. Started Mar 2021; status: completed.
02
Drugs
canakinumab
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on NCT04717635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04717635.